Eton Pharmaceuticals Inc (ETON) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eton Pharmaceuticals Inc   (NASDAQ: ETON)


Eton Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eton Pharmaceuticals Inc's ROI in the third quarter of 2026?
Eton Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 70.98 % in its third quarter of 2026, this is above ETON's average return on investment of -56.01%.
Eton Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2026 $70 million

ROI has improved compared to 21.31% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 45 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 2372 to 2750.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 17.94 % 22.74 % 59.48 % 132.5 % 292.48 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 103 71 54 54 60
Return On Investment (TTM) 70.98 % 21.31 % -2.56 % -7.81 % -11.22 %
ETON's Overall Ranking # 2750 # 2372 # 2531 # 2325 #
Seq. Investment Change TTM 17.99 % 3.3 % -2.19 % -1.07 % 22.79 %
Seq. Net Income Change TTM 293 % - - - -
Net Income (TTM) in Millions 50 13 -1 -5 -7

ETON Company Profile >> Back to ETON Roi Comparisons >> See Annual ETON Return On Investment



Return On Investment ETON's Ranking
Within: No.
Industry # 23
Sector # 46
Overall # 2750

Return On Investment Statistics
High Average Low
21.31 %
-56.01 %
-230.03 %
(Jun 30 2026)   (Sep 30 2018)



  News about Eton Pharmaceuticals Inc Return on Investment ROI

Eton Pharmaceuticals' Hydrocortisone Oral Solution Prepares for FDA Decision as Share Price Rises

July 15, 2024



In an exciting development for Eton Pharmaceuticals, the company recently announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ET-400, a Hydrocortisone Oral Solution. The Prescription Drug User Fee Act (PDUFA) target action date for the drug s approval is set for February 28, 2025. As Eton anticipates this decisive date, investors have taken notice, driving ETON shares to a notable 4.57% increase in the last five trading days. Let us delve into the upcoming FDA decision and the reasons behind Eton s soaring stock performance.
The Promise of Hydrocortisone Oral Solution:
ET-400, Eton Pharmaceuticals Hydrocortisone Oral Solution, holds significant promise as a potential treatment option. Hydrocortisone, a steroid hormone, is widely recognized for its anti-inflammatory and immunosuppressive properties. The oral solution aims to provide relief to patients suffering from adrenal insufficiency, a condition caused by a lack of cortisol production by the adrenal glands. If approved, ET-400 could make a substantial difference in the lives of patients, alleviating their symptoms and improving their overall well-being.





Financial Statements
Eton Pharmaceuticals Inc's III. Quarter Investments $ 103 Millions ETON's Balance sheet
Eton Pharmaceuticals Inc's III. Quarter Income $ 35 Millions Quarterly ETON's Income Statement
ETON's Income by Division See ETON's Income by Division


ETON Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 54 56 15 19 23
Y / Y Investment Growth -4.54 % 262.45 % -16.53 % -18.94 % 1.7 %
Net Income in Millions -5 -4 -1 -9 -2
Y / Y Net Income Growth - - - - -
Annual Return On Investment -8.58 % -6.81 % -6.04 % -48.58 % -8.53 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ETON's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ETON's Competitors
Subscribers only: Roi for Eton Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ETON's Customers

Other Ratios
ETON's Roa ETON's Inventory Turnover Ratio ETON's Growth Rates ETON's Dividend Statistics
ETON's Profitability Ratios ETON's Asset Turnover Ratio ETON's Dividend Growth
ETON's Roe ETON's Valuation Ratios ETON's Financial Strength Ratios ETON's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Elutia Inc   152.93 %
Arbutus Biopharma Corp  120.80 %
Indivior Pharmaceuticals Inc   108.22 %
Lensar Inc   94.32 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %

Date modified: 2026-11-06T13:02:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.